Pancreatic Enzyme Replacement Therapy in Cystic Fibrosis
While typically considered a pulmonary disease, cystic fibrosis patients develop significant nutritional complications and comorbidities, especially those who are pancreatic insufficient. Clinicians must have a high suspicion for cystic fibrosis among patients with clinical symptoms of pancreatic in...
Main Authors: | Peter N. Freswick, Elizabeth K. Reid, Maria R. Mascarenhas |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-03-01
|
Series: | Nutrients |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6643/14/7/1341 |
Similar Items
-
Intestinal Absorption of Lipids Using a Pancreatic Enzyme-Free Nutritional Supplement in Patients with Cystic Fibrosis: A Randomized, Double-Blind, Crossover Pilot Trial
by: Tara L. Barto, et al.
Published: (2022-02-01) -
Correlates of Pancreatic Enzyme Replacement Therapy Intake in Adults with Cystic Fibrosis: Results of a Cross-Sectional Study
by: Mette F. Olsen, et al.
Published: (2022-03-01) -
Pancreatic enzyme replacement therapy in cystic fibrosis: dose, variability and coefficient of fat absorption
by: Joaquim Calvo-Lerma, et al. -
Survey of Pancreatic Enzyme Replacement Therapy Dosing Experiences in Adults with Exocrine Pancreatic Insufficiency
by: Dana M. Lewis, et al.
Published: (2023-08-01) -
Exocrine Pancreatic Insufficiency in Children – Challenges in Management
by: Sankararaman S, et al.
Published: (2023-10-01)